Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes

MANCHESTER, NH--(Marketwired - May 29, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, has initiated a...
May 27, 2014 08:01 ET | Source: Boston Therapeutics

Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29

MANCHESTER, NH--(Marketwired - May 27, 2014) - Boston Therapeutics, Inc. (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today...
May 20, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Announces Strategic Marketing Agreement With Benchworks SD Aimed at Growing Sales of SUGARDOWN(R)

MANCHESTER, NH--(Marketwired - May 20, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) a leading developer of compounds that address blood sugar management and inflammatory disease using complex...
May 13, 2014 12:22 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Corporate Update and Financial Results for the First Quarter Ended March 31, 2014

MANCHESTER, NH--(Marketwired - May 13, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes using...
May 06, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Signs Agreement With Patheon to Manufacture Pharmaceutical-Grade BTI-320 Tablets

MANCHESTER, NH--(Marketwired - May 6, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovator compounds that address diabetes and inflammatory diseases using complex...
April 29, 2014 06:15 ET | Source: Boston Therapeutics

Boston Therapeutics to Present Late-Breaking Poster on Mechanism of Action for BTI-320 at AACE Annual Congress in Las Vegas on May 14-18

MANCHESTER, NH--(Marketwired - Apr 29, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a clinical stage developer of innovative compounds that address diabetes and inflammatory diseases using...
March 17, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Corporate Update and Financial Results for the Fourth Quarter and Year Ended December 31, 2013

MANCHESTER, NH--(Marketwired - Mar 17, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes...
March 04, 2014 07:18 ET | Source: Boston Therapeutics

Boston Therapeutics to Initiate a Phase II Clinical Study of BTI-320 in U.S.

MANCHESTER, NH--(Marketwired - Mar 4, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of compounds that address diabetes using...
February 25, 2014 07:00 ET | Source: Boston Therapeutics, Inc.

Boston Therapeutics Appoints Larry K. Ellingson, Former Chair of the American Diabetes Association, as Chair of Its Scientific Advisory Board

MANCHESTER, NH--(Marketwired - Feb 25, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...
February 11, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Signs Agreement to Market SugarDown(R) in the U.S.

MANCHESTER, NH--(Marketwired - Feb 11, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex...